Lisa M. Ferri is a partner in Mayer Brown's Intellectual Property practice and serves as the IP Practice Leader for the New York Office. She focuses her practice on the trial and appeal of patent matters in the Life Sciences field, including representing innovator companies in cases brought pursuant to the Hatch-Waxman Act. Lisa serves as lead counsel on behalf of high-profile companies in federal courts across the country, Patent Office inter partes reviews, the International Trade Commission and the Federal Circuit Court of Appeals.
Lisa has been recognized by clients and peers as a leading lawyer in intellectual property. She was named one of the "Top 250 Women in IP" by Managing Intellectual Property and was named a leading lawyer in Who’s Who Legal: Patents 2016. Lisa was recognized by IAM Patent 1000 as "spectacular . . . [she] demonstrates a lot of powerful qualities as a patent litigator" and is "extremely persuasive." She was named a "Life Sciences Star" and an "IP Star" by the Legal Media Group, which noted that "Lisa is professional, intelligent, people savvy, tough when need be, and has a great command of the applicable law." Lisa was nominated in 2014 as "Hatch-Waxman Litigator of the Year" by the LMG Life Sciences Awards. In addition, she has been recognized in the area of patent litigation by the Legal 500. Her recent victory at the Federal Circuit Court of Appeals in Biogen IDEC, Inc. and Genentech v. GlaxoSmithKline, which involved the monoclonal antibody therapy Arzerra®, was shortlisted for "Patent Impact Case of the Year" by the LMG Life Sciences Awards.
Lisa's life sciences practice spans a broad range of therapeutic areas and technologies—from pharmaceuticals and biologics for the treatment of HIV/AIDS, cancer, hepatitis, influenza, auto-immunities, anemia, emesis and BPH, to drug delivery systems, research tools, recombinant DNA, RNAi and a variety of medical devices. Her pharmaceutical practice focuses on representing innovator companies in cases brought pursuant to the Hatch-Waxman Act. She has successfully defended a number of key blockbuster drugs. Following enactment of the AIA, Lisa handled one of the first co-pending inter partes reviews and district court litigations relating to the Orange Book listed drug Lexiva® -- which was the first "lead compound" IPR before the PTAB as well. Lisa also concentrates on patent litigation dealing with large molecule biologics products including a series of antibody litigations involving the well-known "Cabilly" patent portfolio.
Lisa is an adjunct professor at Fordham University School of Law where she teaches Patent Litigation.
Lisa serves as co-chair of the firm's global Women's Leadership Committee.